LIGAND PHARMACEUTICALS INCORPORATED Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
LIGAND PHARMACEUTICALS INCORPORATED (LGNZZ) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings of $7.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings · last filed 2026-08-07
- LIGAND PHARMACEUTICALS INCORPORATED fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2026-06-30 was $0.00.
- LIGAND PHARMACEUTICALS INCORPORATED fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2026-03-31 was $7.00K, a 87.27% decline year-over-year.
- LIGAND PHARMACEUTICALS INCORPORATED fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2025-12-31 was $5.00K, a 96.88% decline year-over-year.
- LIGAND PHARMACEUTICALS INCORPORATED fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2025-09-30 was $39.00K.
- LIGAND PHARMACEUTICALS INCORPORATED fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2025 was $62.00K, a 76.43% decline from fiscal 2024.
- LIGAND PHARMACEUTICALS INCORPORATED fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2024 was $263.00K, a 8.04% decline from fiscal 2023.
- LIGAND PHARMACEUTICALS INCORPORATED fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2023 was $286.00K.
- LIGAND PHARMACEUTICALS INCORPORATED fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2022 was -$265.00K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $7.00K 10-Q · filed 2026-08-07 | $12.00K derived: sum of 3 quarters · filed 2026-08-07 | $51.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $7.00K 10-Q · filed 2026-05-08 | $12.00K derived: sum of 2 quarters · filed 2026-05-08 | $51.00K derived: sum of 3 quarters · filed 2026-05-08 | $14.00K derived: sum of 4 quarters · filed 2026-05-08 |
| 2025-12-31 | $5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $44.00K derived: sum of 2 quarters · filed 2026-02-27 | $7.00K derived: sum of 3 quarters · filed 2026-02-27 | $62.00K 10-K · filed 2026-02-27 |
| 2025-09-30 | $39.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $2.00K derived: sum of 2 quarters · filed 2025-11-07 | $57.00K 10-Q · filed 2025-11-07 | $217.00K derived: sum of 4 quarters · filed 2026-02-27 |
| 2025-06-30 | -$37.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $18.00K 10-Q · filed 2025-08-08 | $178.00K derived: sum of 3 quarters · filed 2026-02-27 | $137.00K derived: sum of 4 quarters · filed 2026-02-27 |
| 2025-03-31 | $55.00K 10-Q · filed 2025-05-09 | $215.00K derived: sum of 2 quarters · filed 2026-02-27 | $174.00K derived: sum of 3 quarters · filed 2026-02-27 | $270.00K derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-12-31 | $160.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $119.00K derived: sum of 2 quarters · filed 2026-02-27 | $215.00K derived: sum of 3 quarters · filed 2026-02-27 | $263.00K 10-K · filed 2026-02-27 |
| 2024-09-30 | -$41.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $55.00K derived: sum of 2 quarters · filed 2024-11-08 | $103.00K 10-Q · filed 2024-11-08 | |
| 2024-06-30 | $96.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $144.00K 10-Q · filed 2024-08-07 | ||
| 2024-03-31 | $48.00K 10-Q · filed 2024-05-08 | |||
| 2023-12-31 | $286.00K 10-K · filed 2025-02-28 | |||
| 2022-12-31 | -$265.00K 10-K · filed 2024-02-29 |